Identification and Experimental Validation of the Prognostic Significance and Immunological Correlation of Glycosylation-Related Signature and ST6GALNAC4 in Hepatocellular Carcinoma

References

• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. doi:10.1038/s41571-018-0073-4
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2021;7(1):113–123. doi:10.1001/jamaoncol.2020.3381
   PubMed Web of Science ®Google Scholar
• Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15(6):346–366. doi:10.1038/s41581-019-0129-4
   PubMed Web of Science ®Google Scholar
• Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. CELL. 2006;126(5):855–867. doi:10.1016/j.cell.2006.08.019
   PubMed Web of Science ®Google Scholar
• Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012;13(7):448–462. doi:10.1038/nrm3383
   PubMed Web of Science ®Google Scholar
• Xu C, Ng DT. Glycosylation-directed quality control of protein folding. Nat Rev Mol Cell Biol. 2015;16(12):742–752. doi:10.1038/nrm4073
   PubMed Web of Science ®Google Scholar
• Smith BAH, Bertozzi CR. The clinical impact of glycobiology: targeting selectins, siglecs and mammalian glycans. Nat Rev Drug Discov. 2021;20(3):217–243. doi:10.1038/s41573-020-00093-1
   PubMed Web of Science ®Google Scholar
• Bard F, Chia J. Cracking the glycome encoder: signaling, trafficking, and glycosylation. Trends Cell Biol. 2016;26(5):379–388. doi:10.1016/j.tcb.2015.12.004
   PubMed Web of Science ®Google Scholar
• Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21(12):729–749. doi:10.1038/s41580-020-00294-x
   PubMed Web of Science ®Google Scholar
• Aebi M. N-linked protein glycosylation in the ER. Biochim Biophys Acta. 2013;1833(11):2430–2437. doi:10.1016/j.bbamcr.2013.04.001
   PubMed Web of Science ®Google Scholar
• Gill DJ, Clausen H, Bard F. Location, location, location: new insights into O-GalNAc protein glycosylation. Trends Cell Biol. 2011;21(3):149–158. doi:10.1016/j.tcb.2010.11.004
   PubMed Web of Science ®Google Scholar
• Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188464. doi:10.1016/j.bbcan.2020.188464
   PubMed Web of Science ®Google Scholar
• Mereiter S, Balmana M, Campos D, Gomes J, Reis CA. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell. 2019;36(1):6–16. doi:10.1016/j.ccell.2019.06.006
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–555. doi:10.1038/nrc3982
   PubMed Web of Science ®Google Scholar
• Oliveira-Ferrer L, Legler K, Milde-Langosch K. Role of protein glycosylation in cancer metastasis. Semin Cancer Biol. 2017;44:141–152. doi:10.1016/j.semcancer.2017.03.002
   PubMed Web of Science ®Google Scholar
• RodrIguez E, Schetters STT, van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol. 2018;18(3):204–211. doi:10.1038/nri.2018.3
   PubMed Web of Science ®Google Scholar
• Laubli H, Borsig L. Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis. Front Immunol. 2019;10:2120. doi:10.3389/fimmu.2019.02120
   PubMed Web of Science ®Google Scholar
• Rodrigues JG, Balmana M, Macedo JA, et al. Glycosylation in cancer: selected roles in tumour progression, immune modulation and metastasis. Cell Immunol. 2018;333:46–57. doi:10.1016/j.cellimm.2018.03.007
   PubMed Web of Science ®Google Scholar
• Pereira MS, Alves I, Vicente M, et al. Glycans as key checkpoints of T cell activity and function. Front Immunol. 2018;9:2754. doi:10.3389/fimmu.2018.02754
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang HL, Li ZL, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021;12(1):2672. doi:10.1038/s41467-021-22618-x
   PubMed Web of Science ®Google Scholar
• Song X, Zhou Z, Li H, et al. Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers. Cancer Discov. 2020;10(12):1872–1893. doi:10.1158/2159-8290.CD-20-0402
   PubMed Web of Science ®Google Scholar
• Liu K, Tan S, Jin W, et al. N-glycosylation of PD-1 promotes binding of camrelizumab. EMBO Rep. 2020;21(12):e51444. doi:10.15252/embr.202051444
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Xia W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632. doi:10.1038/ncomms12632
   PubMed Web of Science ®Google Scholar
• Dai Z, Liu YK, Cui JF, et al. Identification and analysis of altered alpha1,6-fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics. 2006;6(21):5857–5867. doi:10.1002/pmic.200500707
   PubMed Web of Science ®Google Scholar
• Kudo T, Nakagawa H, Takahashi M, et al. N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol Cancer. 2007;6:32. doi:10.1186/1476-4598-6-32
   PubMed Web of Science ®Google Scholar
• Verhelst X, Geerts A, Callewaert N, Van Vlierberghe H. The potential of glycomics as prognostic biomarkers in liver disease and liver transplantation. Acta Gastroenterol Belg. 2019;82(2):309–313.
   PubMed Web of Science ®Google Scholar
• de Oliveira RM, Ornelas Ricart CA, Araujo Martins AM. Use of mass spectrometry to screen glycan early markers in hepatocellular carcinoma. Front Oncol. 2017;7:328. doi:10.3389/fonc.2017.00328
   PubMed Web of Science ®Google Scholar
• Watson ME, Diepeveen LA, Stubbs KA, Yeoh GC. Glycosylation-related diagnostic and therapeutic drug target markers in hepatocellular carcinoma. J Gastrointestin Liver Dis. 2015;24(3):349–357. doi:10.15403/jgld.2014.1121.243.mew
   PubMed Web of Science ®Google Scholar
• Mehta A, Herrera H, Block T. Glycosylation and liver cancer. Adv Cancer Res. 2015;126:257–279. doi:10.1016/bs.acr.2014.11.005
   PubMed Web of Science ®Google Scholar
• Mendez-Huergo SP, Blidner AG, Rabinovich GA. Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis. Curr Opin Immunol. 2017;45:8–15. doi:10.1016/j.coi.2016.12.003
   PubMed Web of Science ®Google Scholar
• Chan LC, Li CW, Xia W, et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129(8):3324–3338. doi:10.1172/JCI126022
   PubMed Web of Science ®Google Scholar
• Harduin-Lepers A, Stokes DC, Steelant WF, et al. Cloning, expression and gene organization of a human Neu5Ac alpha 2-3Gal beta 1-3GalNAc alpha 2,6-sialyltransferase: hST6GalNAcIV. Biochem J. 2000;352(Pt 1):37–48. doi:10.1042/bj3520037
   PubMedGoogle Scholar
• Miao X, Jia L, Zhou H, et al. miR-4299 mediates the invasive properties and tumorigenicity of human follicular thyroid carcinoma by targeting ST6GALNAC4. IUBMB Life. 2016;68(2):136–144. doi:10.1002/iub.1467
   PubMed Web of Science ®Google Scholar
• Reticker-Flynn NE, Bhatia SN. Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Cancer Discov. 2015;5(2):168–181. doi:10.1158/2159-8290.CD-13-0760
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao W, Zhao Y, He Q. Expression of ST3Gal, ST6Gal, ST6GalNAc and ST8Sia in human hepatic carcinoma cell lines, HepG-2 and SMMC-7721 and normal hepatic cell line, L-02. Glycoconj J. 2015;32(1–2):39–47. doi:10.1007/s10719-014-9569-z
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19(5):287–305. doi:10.1038/s41571-022-00601-9
   PubMed Web of Science ®Google Scholar
• Zhou S, Zhu J, Xu J, et al. Anti-tumour potential of PD-L1/PD-1 post-translational modifications. Immunology. 2022;167(4):471–481. doi:10.1111/imm.13573
   PubMed Web of Science ®Google Scholar
• Larsen ISB, Narimatsu Y, Clausen H, Joshi HJ, Halim A. Multiple distinct O-Mannosylation pathways in eukaryotes. Curr Opin Struct Biol. 2019;56:171–178. doi:10.1016/j.sbi.2019.03.003
   PubMed Web of Science ®Google Scholar
• Ostergaard ST, Johnson K, Stojkovic T, et al. Limb girdle muscular dystrophy due to mutations in POMT2. J Neurol Neurosurg Psychiatry. 2018;89(5):506–512. doi:10.1136/jnnp-2017-317018
   PubMed Web of Science ®Google Scholar
• Johnson K, Bertoli M, Phillips L, et al. Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole-exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness. Skelet Muscle. 2018;8(1):23. doi:10.1186/s13395-018-0170-1
   PubMedGoogle Scholar
• Carvalho S, Oliveira T, Bartels MF, et al. O-mannosylation and N-glycosylation: two coordinated mechanisms regulating the tumour suppressor functions of E-cadherin in cancer. Oncotarget. 2016;7(40):65231–65246. doi:10.18632/oncotarget.11245
   PubMedGoogle Scholar
• Kumari K, Das B, Adhya AK, Rath AK, Mishra SK. Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival. Sci Rep. 2019;9(1):1974. doi:10.1038/s41598-019-39122-4
   PubMedGoogle Scholar